NovAb is developing a new class of antibodies, variable lymphocyte receptors (“VLRs”), discovered by our founding scientist, Dr. Max Cooper (Emory). VLRs are the immune receptors of jawless vertebrates, are composed of highly diverse leucine rich repeat structural motifs, and possess a rigid β-sheet binding site contained in a single polypeptide. Our premise in forming NovAb is that the evolutionary distance of jawless vertebrates and the distinctive VLR binding site structure would provide specificities distinct from those of conventional Ig antibodies: now well-confirmed. NovAb’s lead therapeutic products are chimeric antigen receptor (“CAR”) and T cell activating bispecific antibody ("TABA") therapies that target a novel specificity unique to plasma cells (PCs) and multiple myeloma (MM) cancers. NovAb’s MM3 CAR-T and TABA have demonstrated specific, potent depletion of MM tumors and PCs, including PCs responsible for autoimmune and organ transplant rejection antibodies.